Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX)

Heikki JoensuuDepartment of Oncology, Helsinki University Central Hospital, Helsinki, FinlandCorrespondence[email protected]

Pirkko-Liisa Kellokumpu-LehtinenDepartment of Oncology, Tampere University Hospital, Tampere, Finland

Riikka HuovinenDepartment of Oncology, Turku University Central Hospital, Turku, Finland

Arja Jukkola-VuorinenDepartment of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland

Minna TannerDepartment of Oncology, Tampere University Hospital, Tampere, Finland

Riitta KokkoKanta-Häme Central Hospital, Hämeenlinna, Finland

Johan AhlgrenGävle Hospital, Gävle, Sweden

Päivi AuvinenCancer Center, Kuopio University Hospital, Kuopio, Finland

Outi SaarniDepartment of Oncology, Turku University Central Hospital, Turku, Finland;Satakunta Central Hospital, Pori, Finland

Leena HelleKotka Central Hospital, Kotka, Finland

Kenneth VillmanÖrebro University Hospital, Örebro, Sweden

Paul NyandotoPäijät-Häme Central Hospital, Lahti, Finland

Greger NilssonUppsala University Hospital, Uppsala, Sweden

Mika Leinonen4Pharma, Turku, Finland

Vesa KatajaCancer Center, Kuopio University Hospital, Kuopio, Finland;Vaasa Central Hospital, Vaasa, Finland

Petri BonoDepartment of Oncology, Helsinki University Central Hospital, Helsinki, Finland

Henrik LindmanUppsala University Hospital, Uppsala, Sweden

Your download is now in progress and you may close this window